The revertant activity of different compounds has been assayed on a multidrug-resistant human breast-cancer cell line (MCF 7/Dx). The calcium-channel blocker nicardipine showed the higher revertant ability when compared to cefoperazone or cyclosporin A at concentrations close to the pharmacological range. Interestingly, nicardipine was able to increase the revertant activities of both cefoperazone and cyclosporin A, but these latter were not able to enhance each other over a plateau. However, a limit of about 70% of growth inhibition of the line cultured in the presence of 60 muM doxorubicin seems to be insuperable at the concentrations employed. The combination of the three drugs brings the concentrations of drugs to the point at which the maximum possible inhibition is reached in the pharmacological range, but the complete reversion of chemoresistance is not reached when the doxorubicin is added at the concentration capable of reducing the cell proliferation by 50%.

Activity of different revertant agents on multidrug resistance: in vitro evaluation of their combination

PETRINI, MARIO;MATTII, LETIZIA;SABBATINI, ANTONIETTA RAFFAELLA MARIA;RONCA, GIOVANNI
1993-01-01

Abstract

The revertant activity of different compounds has been assayed on a multidrug-resistant human breast-cancer cell line (MCF 7/Dx). The calcium-channel blocker nicardipine showed the higher revertant ability when compared to cefoperazone or cyclosporin A at concentrations close to the pharmacological range. Interestingly, nicardipine was able to increase the revertant activities of both cefoperazone and cyclosporin A, but these latter were not able to enhance each other over a plateau. However, a limit of about 70% of growth inhibition of the line cultured in the presence of 60 muM doxorubicin seems to be insuperable at the concentrations employed. The combination of the three drugs brings the concentrations of drugs to the point at which the maximum possible inhibition is reached in the pharmacological range, but the complete reversion of chemoresistance is not reached when the doxorubicin is added at the concentration capable of reducing the cell proliferation by 50%.
1993
Petrini, Mario; Mattii, Letizia; Sabbatini, ANTONIETTA RAFFAELLA MARIA; Conte, A; Grassi, B; Ronca, Giovanni
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/202741
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact